AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. This time, the U.S. pharma is paying Xilio Therapeutics $52 million upfront to work on antibody-based immunotherapies.
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. This time, the U.S. pharma is paying Xilio Therapeutics $52 million upfront to work on antibody-based immunotherapies.
